UK markets open in 42 minutes
  • NIKKEI 225

    27,327.11
    -106.29 (-0.39%)
     
  • HANG SENG

    21,703.55
    -366.18 (-1.66%)
     
  • CRUDE OIL

    77.49
    -0.41 (-0.53%)
     
  • GOLD FUTURES

    1,930.60
    -8.60 (-0.44%)
     
  • DOW

    33,717.09
    -260.99 (-0.77%)
     
  • BTC-GBP

    18,528.42
    -736.17 (-3.82%)
     
  • CMC Crypto 200

    519.28
    -18.59 (-3.46%)
     
  • ^IXIC

    11,393.81
    -227.90 (-1.96%)
     
  • ^FTAS

    4,265.16
    +6.19 (+0.15%)
     

Laxxon Medical to Participate in 25th Annual Needham Growth Conference


New York, 01/05/2023 / 08:00, EST/EDT - EQS Newswire - Laxxon Medical


NEW YORK, NY / ACCESSWIRE / January 5, 2023 / Laxxon Medical Corporation announced today their invitation to participate as a private company in the 25th Annual Needham Growth Conference at the Lotte New York Palace Hotel on January 10-12, 2023.

Helmut Kerschbaumer, CEO/Chairman, and Alexander Ruckdaeschel, Chief Strategy Officer, will hold one-on-one meetings with institutional, private equity, and venture capital investors throughout the day on January 12, 2023.

About Laxxon Medical Corporation

Laxxon Medical is a pharma-technology company pioneering innovative 3D screen printed pharmaceutical solutions through SPID®-Technology (Screen Printing Innovational Drug Technology), an additive 3D screen printing technology and manufacturing process. Laxxon Medical holds the exclusive worldwide rights to the use and application of SPID®-Technology for the development, manufacture, and commercialization of pharmaceutical dosage forms.

For more information, visit www.laxxonmedical.com or follow Laxxon Medical on LinkedIn or Twitter.

Investor Contact:

Alexander Ruckdaeschel
Chief Strategy Director
a.ruckdaeschel@laxxonmedical.com

Media Contact:

Frances Hoggard
Communications Manager
f.hoggard@laxxonmedical.com

SOURCE: Laxxon Medical Corporation



01/05/2023 EQS Newswire / EQS Group AG



show this
show this